Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation

NCT06780930 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Residual or Recurrent Grade 2 IDH Mutant Glioma

Interventions

DRUG: Vorasidenib
DRUG: Placebo

Sponsor

Servier